Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.
Volume 30, Number 8—August 2024
Dispatch
Hepatitis B Virus Reactivation After Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody
Table 2
Laboratory values over time of a person in Japan with HIV 2 years before changing ART regimen to CAB/RPV and the period while on CAB/RPV, showing HBV reactivation in month 4*
Time from ART change | –2 y | 0 mo | 1 mo | 2 mo | 4 mo | 6 mo | 8 mo | 10 mo | 14 mo |
---|---|---|---|---|---|---|---|---|---|
ART regimen |
B/F/TAF |
CAB/ RPV oral |
CAB/RPV injectable |
CAB/RPV |
CAB/RPV |
CAB/RPV |
CAB/RPV |
CAB/RPV |
B/F/TAF |
Laboratory values | |||||||||
Anti-HBs, IU/mL† | N/A | 6.57 | 5.65 | 8.78 | 0.20 | 0.20 | 0.00 | 0.13 | 0.00 |
HBsAg, mIU/mL‡ | 0.00 | 0.00 | 0.00 | 0.00 | 816 | 90,332 | 124,890 | 143,785 | 131,765 |
Anti-HBe, inhibition %§ | NA | NA | NA | Negative | 6.16 | 31.1 | 54.4 | 56.0 | 55.3 |
HBeAg, S/CO¶ | NA | NA | NA | Negative | 60.5 | 404 | 680 | 835 | 915 |
HBV DNA, log copies/mL | ND | NA | NA | NA | 3.9 | NA | NA | NA | 8.2 |
ALT, U/L | 66 | 25 | 0 | 25 | 103 | 158 | 40 | 32 | 27 |
Total bilirubin, mg/dL | 0.4 | 0.6 | 0.5 | 0.6 | 0.5 | 0.6 | 0.6 | 0.7 | 0.4 |
HBcrAg, Log U/mL# | NA | NA | Negative | NA | NA | NA | NA | NA | >7.1 |
*ALT, alanine aminotransferase; anti-HBe, hepatitis B e-antibody; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; CAB, cabotegravir; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; NA, not applicable; ND, not detected; RPV, rilpivirine. †Cutoff value 10 IU/mL. ‡Cutoff value 10 mIU/mL. §Cutoff value 50% inhibition. ¶Cutoff value 1.0 S/CO. #Cutoff value 3.0 log U/mL.
1These first authors contributed equally to this article.